• About us
  • People
  • Expertise
    • Sectors
        • Technology, media & communications Technology, media & communications
        • Private Wealth Private wealth
        • Real estate, infrastructure & energy
        • Life sciences & healthcare icon Life sciences & healthcare
        • Aerospace & defence
        • Automotive & mobility
        • Business & professional services
        • Chemicals
        • Consumer & retail
        • Financial institutions & insurance
        • Hotels, hospitality & leisure
        • Logistics & transport
        • Manufacturing & industrials
        • Public services & education
    • Legal services
        • Artificial intelligence
        • Banking & finance
        • Brands & advertising
        • Commercial & consumer contracts
        • Competition, EU & trade
        • Copyright & media law
        • Corporate crime & compliance
        • Corporate/M&A & capital markets
        • Data & cyber
        • Disputes & investigations
        • Employment, pensions & mobility
        • Environmental, planning & regulatory
        • Environmental, social & governance (ESG)
        • Information technology
        • Multi-service
        • Patents & innovation
        • Private client
        • Private equity
        • Projects, energy & infrastructure
        • Real estate & construction
        • Regulation
        • Restructuring & insolvency
        • Tax
        • Venture capital
  • Locations
    • Europe
        • Locations
        • Austria
        • Belgium
        • Czech Republic
        • France
        • Germany
        • Hungary
        • Italy
        • Netherlands
        • Poland
        • Portugal
        • Ireland
        • Slovakia
        • Spain
        • United Kingdom
        • Ukraine
          Groups & regions
        • CEE Turkish Desk
        • French German group
        • Our offices
    • Middle East & Africa
        • Locations
        • Middle East
        • UAE
          Groups
        • Africa group
        • Israel group
        • Our offices
    • Americas
        • Locations
        • Latin America
        • USA
          Groups
        • Brazil group
        • Our offices
    • Asia
        • Locations
        • Asia
        • China
        • South Korea
          Groups
        • India group
        • Japan group
        • Our offices
  • Insights
    • Insights
        • Featured Topics
        • Artificial intelligence
        • Data Centre Expertise
        • The EU Whistleblower Directive
        • German Supply Chain Act
        • Unified Patent Court
          Content hub
        • Global Data Hub
        • Interface: tech, IP and media law
        • Podcasts
        • Synapse
        • Browse All Insights
    • Events
        • In person
        • Online
        • Browse All Events
    • News
        • Media centre
        • Work highlights
        • Firm news
        • Browse all news
  • Careers
  • EN
    • English
    • 中文(简体)
    • Français
    • Deutsch
  • Home
  • People
  • Matthew Royle
Matthew Royle, Ph.D.
Matthew Royle, Ph.D.

Matthew Royle, Ph.D.

Partner

  • London UK
Contact Me Today
+44 20 7300 4608
vCard
Email me Call me
Featured award

Managing Intellectual Property – IP Stars 2024

Patent star

Scroll to featured award

Matthew specialises in patent litigation, opinion work, supplementary protection certificates (SPCs), paediatric extensions and regulatory advice.

Matthew has a strong science background, holding a PhD in molecular immunology, meaning he gets to grips with the scientific facts of a case quickly.

A leading individual in Chambers and is a rising star in litigation, Matthew has particular experience of acting for clients in the pharmaeutical, biotech and life sciences sectors.  He regularly co-ordinates pan-European litigation and has been involved in hearings in Germany, Netherlands, Belgium and Norway.

Expertise

Services and Groups

Patents & innovation
Disputes & investigations
Healthcare regulatory
IP disputes
Technology disputes
Advising on life sciences regulation
Resolving patents & know-how disputes

Sectors

Life sciences & healthcare
Biotech
Medical devices
Pharmaceuticals

Patent Perspective Quick Listens

A UPC and European patent litigation podcast.

Listen now

CV

Since 2015 Partner, Taylor Wessing
2011 - 2015 Senior Associate, Taylor Wessing
2006 - 2011 Associate, Taylor Wessing
2004 - 2006 Trainee solicitor, Taylor Wessing
2007 Diploma in Intellectual Property Law, Bristol University, UK
2006 Admitted to the Bar, England and Wales
2002 PhD, Molecular Immunology, University of Cambridge, UK
1998 Degree, Medical Microbiology, University of Edinburgh, UK

Career

Since 2015 Partner, Taylor Wessing
2011 - 2015 Senior Associate, Taylor Wessing
2006 - 2011 Associate, Taylor Wessing
2004 - 2006 Trainee solicitor, Taylor Wessing

Education

2007 Diploma in Intellectual Property Law, Bristol University, UK
2006 Admitted to the Bar, England and Wales
2002 PhD, Molecular Immunology, University of Cambridge, UK
1998 Degree, Medical Microbiology, University of Edinburgh, UK

Publications

EU Guidance on biosimilar MAbs - what took so long?, Scrip Regulatory Affairs, pp 10-12, 17, July 2012
Neurim - EU Advocate General argues that supplementary protection certificates should be allowed for usage patents, Scrip Regulatory Affairs, p 5, 22, May 2012

Memberships & Associations

Associate member of CIPA

Additional languages

English

Awards

Managing Intellectual Property – IP Stars 2024

Featured

Patent star

Chambers and Partners UK 2023

Life Sciences (IP/patent litigation) - Band 2: Matthew Royle frequently represents pharmaceutical manufacturers in contentious work regarding patent infringement claims, revocation actions and secondary use SPCs. Prior to his legal career he undertook a doctorate in medical microbiology. "A well-respected litigator." "Matthew Royle is clearly very clever and good at managing challenging situations."

Chambers and Partners UK 2023

Intellectual Property (patent litigation) - Band 3: Matthew Royle acts for pharmaceutical companies in patent litigation and also advises them on SPCs and regulation. He has taken a number of cases to the UK Supreme Court.

Chambers UK 2022

Life Sciences - IP/Patent Litigation: "A good litigator, with a good knowledge of the life sciences sector. He has a particular focus on the generics side."

Intellectual Property - Patent Litigation

"The Impact Case of the Year" for Actavis v ICOS case, where we acted for Mylan in relation to litigation on two patents relating to Lilly's blockbuster drug Cialis® (tadalafil).

Leading individual - Life Sciences: IP/Patent (band 3) and IP: patent litigation (band 4).

Leading individual - Life Sciences: IP/Patent litigation (Band 3): Matthew Royle frequently represents pharmaceutical manufacturers in contentious work regarding patent infringement claims, revocation actions and secondary use SPCs. A source says: "He is a very good patent litigator – sensible, pragmatic and a pleasure to work with."

Leading individual - Intellectual Property: Patent litigation (Band 4): Matthew Royle acts for pharmaceuticals companies in patent litigation and also advises them on SPCs and regulation. A source says: "He is a very good patent litigator - sensible, pragmatic and a pleasure to work with."

Leading individual - TMT: Pharmaceuticals and Biotech

Leading individual: litigation (Bronze): Matthew Royle is a canny and highly trained harvester of SPC extensions – a “well-known, longstanding presence in intellectual property”.

Leading individual: Patents

Patent star

For Pregabalin Supreme Court case

Leading individual - Intellectual Property: Patent Litigation (Band 4): Matthew Royle is a patent litigator and pharmaceuticals regulation expert with an academic background in medical microbiology. A source says: "He is a real hands-on partner in a lot of major cases."

Leading individual - Life Sciences: IP/Patent Litigation (Band 3): Matthew Royle is known for representing generic pharmaceutical manufacturers in high-stakes patent litigation such as patent revocation actions and disputes concerning contested SPCs. A source says: "He is a real hands-on partner in a lot of major cases."

Leading individual - Intellectual Property: Patent Litigation (Band 4): Matthew Royle is a rising life sciences patent litigator whose recent work has involved questions of secondary medical uses, dosage regimes and SPCs. A market commentator says he is "very strong on the science."

Leading individual - Life Sciences: IP/Patent Litigation (Band 3): Matthew Royle is distinguished for his representation of generic pharmaceutical manufacturers in high-value patent revocation actions and cases concerning SPCs. Sources note that he is "very strong on the science."

‘Rising star’ in litigation

Experience

A life sciences company

A life sciences company on market formation dates in relation to orphan medicinal products.

Matthew Royle, Ph.D.

A life sciences company

A life sciences company on the validity of and expiry of supplementary protection certificates for a product launch.

Matthew Royle, Ph.D.

A life sciences company

A life sciences company on an EPO opposition in relation to a pharmaceutical.

Matthew Royle, Ph.D.

A company dealing with commercialisation arrangements for university discoveries

A company dealing with commercialisation arrangements for university discoveries on a dispute between co-inventors in relation to a patent.

Matthew Royle, Ph.D.

A life sciences company

A life sciences company on data exclusivity in relation to a combination product in the context of a sale of that product.

Matthew Royle, Ph.D.

Matthew's news & insights

View Matthew's insights
Patent Perspectives Quick Listens - Episode 5
Click here to find out more
Patents & innovation

Episode 5: How is substantive law developing in the Unified Patent Court (UPC)?

17 March 2025

by multiple authors

Glass.Mapper.Sc.Fields.Image?.Alt
UPC

Good news for patent proprietors: the CoA's decision on the requirements for withdrawing an opt-out

25 November 2024
In-depth analysis

by multiple authors

Click here to find out more
Glass.Mapper.Sc.Fields.Image?.Alt
Patents & innovation

What is the language of the UPC?

31 July 2024
In-depth analysis

by multiple authors

Click here to find out more
View Matthew's insights

Related news & insights

Pipette adding sample to petri dish
Life sciences & healthcare

Advising SENISCA on its partnership with L'Oréal

4 July 2025

by Colin McCall and Charlie Adams

Click here to find out more
ESG
Environmental, social & governance (ESG)

Green Patents and ESG Innovation: The Role of the European Patent Framework

3 July 2025
Briefing

by Laura Coucke and Adam Lybaert

Click here to find out more
Patterned pills

The Critical Medicines Act: A New Pillar of European Pharmaceutical Resilience

26 June 2025
Briefing

by Alina Krukover

Click here to find out more
Scientist studying molecule model
Life sciences & healthcare

China’s Rare Earth Export Controls: Implications for European Life Sciences Companies

26 June 2025
Briefing

by Dr. Amir-Said Ghassabeh

Click here to find out more
Business team discussing view from above
Life sciences & healthcare

Life Sciences as a Security-Relevant Sector: Is Innovation at Risk under European and German FDI Control?

26 June 2025
Briefing

by Dr. Carolin Roßkothen, LL.M.

Click here to find out more
Scientist studying molecule model
Life sciences & healthcare

Corporate Venturing in Life Sciences: Making Partnerships Truly Strategic

26 June 2025
Quick read
Click here to find out more
Life sciences & healthcare

Higher Regional Court of Frankfurt am Main on online referral of doctors for the prescription of medical cannabis

24 June 2025
In-depth analysis

by Dr. Daniel Tietjen and Ennio Schwind, LL.M. Eur.

Click here to find out more
Laboratory pipettes
Life sciences & healthcare

Request for a preliminary ruling by the BGH to the CJEU on the scope of the duty of care of medical device distributors

23 June 2025
In-depth analysis

by Dr. Daniel Tietjen and Daniel Dietrich

Click here to find out more
Genetically modified wheat growing in a petri dish
Life sciences & healthcare

Appeal proceedings on the admissibility of granting Rx bonuses to a mail-order pharmacy based in the EU

23 June 2025
Briefing

by Dr. Daniel Tietjen and Ennio Schwind, LL.M. Eur.

Click here to find out more
Pills
Life sciences & healthcare

Federal Court of Justice (BGH): Placing medicinal products on the market within the meaning of Section 43 (1) of the German Medicines Act (AMG) when selling pharmacy-only medicines via the Amazon Marketplace

23 June 2025
In-depth analysis

by Dr. Daniel Tietjen and Daniel Dietrich

Click here to find out more
View all insights

Related people

UK
Simon Cohen

Simon Cohen

Partner

London
+44 20 7300 4815
Email me
View profile
Full team

Meet me at

There are no upcoming events

See all events
Subscribe to our latest insights
  • About us
  • Campaigns and online tools
  • News
  • People
  • Expertise
  • Locations
  • Insights
  • Events
  • Media centre
  • Contact
  • Careers
  • Alumni
  • Data protection & privacy policy
  • Cookie policy
  • Legal and regulatory information
  • Regulatory information on costs
  • Complaints procedure for clients
  • Terms of use
  • Anti-slavery statement
  • Environmental
  • Scam emails

© Taylor Wessing